Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Mechanistic and pharmacological assessment of murine IL-23 mediated psoriasiform dermatitis implications for drug discovery

ABSTRACT: Mechanistic and pharmacological assessment of murine IL-23 mediated psoriasiform dermatitis implications for drug discovery

PROVIDER: PRJNA510398 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR8330940.fastq.gz	Fastqsanger.gz
	SRR8330941.fastq.gz	Fastqsanger.gz
	SRR8330942.fastq.gz	Fastqsanger.gz
	SRR8330943.fastq.gz	Fastqsanger.gz
	SRR8330934.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 16

Similar Datasets

Mechanistic and pharmacological assessment of murine IL-23 mediated psoriasiform dermatitis; implications for drug discovery

Project description:The goal of our study is to is to provide a comprehensive disease and pharmacological assessment of IL-23 driven skin inflammation and its similarity to human psoriatic skin.

2018-12-18 | GSE123971 | GEO

RNA-seq of dorsal root ganglion from IMQ-induced psoriasiform dermatitis mice.

Project description:We divided the male C57BL/6 mice into two groups: a non-treatment group and an IMQ-induced psoriasiform dermatitis group. We isolated the C3-C5 ganglia from male mice, then preserved them in RNA stabilization solution. RNA was extracted using Trizol, followed by transcriptome sequencing.

2025-07-31 | GSE276367 | GEO

Single-cell sequencing of dorsal root ganglion from IMQ-induced psoriasiform dermatitis mice.

Project description:We divided the e male C57BL/6 mice into two groups: a non-treatment group and an IMQ-induced psoriasiform dermatitis group. The dorsal root ganglia of the mice were extracted, enzymatically digested, and then enriched using Percoll. Subsequently, single-cell RNA sequencing was performed.

2025-07-31 | GSE302755 | GEO

Influence of rYopM treatment on IMQ-induced psoriasiform dermatitis

Project description:Influence of rYopM treatment on IMQ-induced psoriasiform dermatitis

| PRJNA486825 | ENA

KLK6 expression in skin induces PAR1-mediated psoriasiform dermatitis and inflammatory joint disease

Project description:Kallikrein-related peptidase 6 (KLK6) is a secreted serine protease hypothesized to promote inflammation via cleavage of protease-activated receptors (PAR)1 and PAR2. KLK6 levels are elevated in multiple inflammatory and autoimmune conditions, but no definitive role in pathogenesis has been established. Here, we show that skin-targeted overexpression of KLK6 causes generalized, severe psoriasiform dermatitis with spontaneous development of debilitating psoriatic arthritis-like joint disease. The psoriatic skin and joint phenotypes are reversed by normalization of skin KLK6 levels and attenuated following genetic elimination of PAR1 but not PAR2. Conservation of this regulatory pathway was confirmed in human psoriasis using vorapaxar, an FDA-approved PAR1 antagonist, on explanted lesional skin from psoriasis patients. Beyond defining a critical role for KLK6-PAR1 signaling in promoting psoriasis, our results demonstrate that KLK6-PAR1-mediated inflammation in the skin alone is sufficient to drive inflammatory joint disease. Further, we identify PAR1 as a promising cytokine-independent target in therapy of psoriasis and psoriatic arthritis.

2020-03-25 | GSE144312 | GEO

RNA-seq of dorsal root ganglion from IMQ-induced psoriasiform dermatitis mice.

Project description:RNA-seq of dorsal root ganglion from IMQ-induced psoriasiform dermatitis mice.

| PRJNA1156787 | ENA

Single-cell sequencing of dorsal root ganglion from IMQ-induced psoriasiform dermatitis mice.

Project description:Single-cell sequencing of dorsal root ganglion from IMQ-induced psoriasiform dermatitis mice.

| PRJNA1292105 | ENA

KLK6 expression in skin induces PAR1-mediated psoriasiform dermatitis and inflammatory joint disease

Project description:KLK6 expression in skin induces PAR1-mediated psoriasiform dermatitis and inflammatory joint disease

| PRJNA603350 | ENA

CXCR4 negatively regulates keratinocyte proliferation in IL-23-mediated psoriasiform dermatitis.

Project description:CXCR4 is expressed by basal keratinocytes (KCs), but little is known about its function in inflamed skin. We crossed K14-Cre and CXCR4(flox/flox (f/f)) transgenic mice, resulting in mice with specific loss of the CXCR4 gene in K14-expressing cells (K14-CXCR4KO), including basal KCs. K14-CXCR4KO pups had no obvious skin defects. We compared K14-CXCR4KO and CXCR4(f/f) control mice in an IL-23-mediated psoriasiform dermatitis model and measured skin edema, and histologic and immunohistological changes. IL-23-treated K14-CXCR4KO mice showed a 1.3-fold increase in mean ear swelling, a 2-fold increase in epidermal thickness, and greater parakeratosis. IL-23-treated wild-type (WT) mice showed weak CXCR4 expression in areas of severe epidermal hyperplasia, but strong CXCR4 expression in nonhyperplastic regions, suggesting that CXCR4 may regulate KC proliferation. To test this hypothesis, we overexpressed CXCR4 in HaCaT KC cells and treated them with IL-22 and/or CXCL12 (chemokine (C-X-C motif) ligand 12). CXCL12 blocked IL-22-mediated HaCaT cell proliferation in vitro and synergized with IL-22 in upregulating SOCS3 (suppressor of cytokine signaling 3), a key regulator of STAT3 (signal transducer and activator of transcription 3). SOCS3 was required for CXCR4-mediated growth inhibition. In human psoriatic skin, both CXCR4 and SOCS3 were upregulated in the junctional region at the border of psoriatic plaques. Thus, CXCR4 has an unexpected role in inhibiting KC proliferation and mitigating the effects of proliferative T helper type 17 cytokines.

| S-EPMC3972890 | biostudies-literature

FAM3C/ILEI protein is elevated in psoriatic lesions and triggers psoriasiform hyperproliferation in mice

Project description:Inducible keratinocyte-specific ILEI overexpression in mice (K5-ILEIind) recapitulates many aspects of psoriasis following TPA challenge, primarily manifested by impaired epidermal differentiation and increased neutrophil recruitment. Mechanistically, ILEI triggers Erk and Akt signaling, which then activate STAT3 via Ser727 phosphorylation. Keratinocyte-specific ILEI deletion ameliorates TPA-induced skin inflammation. A transcriptomic ILEI signature obtained from the K5-ILEIind model shows enrichment in several signaling pathways also found in psoriasis and identifies urokinase as a targetable enzyme to counteract ILEI activity. Pharmacological inhibition of urokinase in TPA-induced K5-ILEIind mice results in significant improvement of psoriasiform symptoms by reducing ILEI secretion. The ILEI signature distinguishes psoriasis from healthy skin with uPA ranking among the top “separator” genes. Our study identifies ILEI as a key driver in psoriasis, indicates the relevance of ILEI-regulated genes for disease manifestation and shows the clinical impact of ILEI and urokinase as novel potential therapeutic targets in psoriasis.

2023-04-12 | E-MTAB-12849 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data